Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening

The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated drug targets for the discovery of antimalarial agents. In order to identify dual inhibitors of both proteins, we developed a hierarchical virtual screening approach, followed by in vitro evaluation of the highest scoring hits. Starting from the ZINC database of purchasable compounds, sequential 3D-pharmacophore and molecular docking steps were applied to filter the virtual ‘hits’. At the end of virtual screening, 12 compounds were chosen and tested against the in vitro aminopeptidase activity of both PfA-M1 and PfA-M17. Two molecules showed significant inhibitory activity (low micromolar/nanomolar range) against both proteins. Finally, the crystal structure of the most potent compound in complex with both PfA-M1 and PfA-M17 was solved, revealing the binding mode and validating our computational approach.

[1]  A. Bell,et al.  Characterization of the Plasmodium falciparum M17 Leucyl Aminopeptidase , 2007, Journal of Biological Chemistry.

[2]  J. Dalton,et al.  Synthesis and Structure − Activity Relationships of Phosphonic Arginine Mimetics as Inhibitors of the M 1 and M 17 Aminopeptidases from Plasmodium falciparum , 2013 .

[3]  Lahana,et al.  How many leads from HTS? , 1999, Drug discovery today.

[4]  Woldeamanuel A. Birru,et al.  Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases , 2010, Proceedings of the National Academy of Sciences.

[5]  J. Whisstock,et al.  Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase , 2009, Proceedings of the National Academy of Sciences.

[6]  Keun Woo Lee,et al.  Potent bace-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies , 2011, BMC Bioinformatics.

[7]  David Ryan Koes,et al.  ZINCPharmer: pharmacophore search of the ZINC database , 2012, Nucleic Acids Res..

[8]  Owen Johnson,et al.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.

[9]  N. Cowieson,et al.  MX1: a bending-magnet crystallography beamline serving both chemical and macromolecular crystallography communities at the Australian Synchrotron , 2015, Journal of synchrotron radiation.

[10]  S. McGowan,et al.  X‐ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti‐malarial drug targets PfA‐M1 and PfA‐M17 , 2015, Proteins.

[11]  Thomas Lengauer,et al.  Flexible Docking of Ligands into Synthetic Receptors Using a Two-Sided Incremental Construction Algorithm , 2006, J. Chem. Inf. Model..

[12]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[13]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[14]  J. Whisstock,et al.  Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases , 2011, Proceedings of the National Academy of Sciences.

[15]  J. Whisstock,et al.  Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. , 2010, Trends in biochemical sciences.

[16]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[17]  Lance M. Westerhoff,et al.  Accurate macromolecular crystallographic refinement: incorporation of the linear scaling, semiempirical quantum-mechanics program DivCon into the PHENIX refinement package. , 2014, Acta crystallographica. Section D, Biological crystallography.

[18]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[19]  Matthias Rarey,et al.  Modeling of metal interaction geometries for protein–ligand docking , 2007, Proteins.

[20]  Shailesh N Mistry,et al.  Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors. , 2014, Journal of medicinal chemistry.

[21]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[22]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[23]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[24]  Doris Ma Fat,et al.  WHO Library Cataloguing-in-Publication Data , 2001 .

[25]  Peter Briggs,et al.  A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.

[26]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[27]  J. Whisstock,et al.  Fingerprinting the Substrate Specificity of M1 and M17 Aminopeptidases of Human Malaria, Plasmodium falciparum , 2012, PloS one.

[28]  Yu-chian Chen.  Beware of docking! , 2015, Trends in pharmacological sciences.

[29]  John R. Helliwell,et al.  Experiences with making diffraction image data available: what metadata do we need to archive? , 2014, Acta crystallographica. Section D, Biological crystallography.

[30]  Matthias Rarey,et al.  A consistent description of HYdrogen bond and DEhydration energies in protein–ligand complexes: methods behind the HYDE scoring function , 2012, Journal of Computer-Aided Molecular Design.

[31]  D. Sullivan,et al.  Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. , 1997, Annual review of microbiology.

[32]  Shailesh N Mistry,et al.  Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18 , 2015, PloS one.

[33]  Elizabeth A. Winzeler,et al.  Antimalarial drug discovery — approaches and progress towards new medicines , 2017, Nature Reviews Microbiology.